Chikungunya
CHIKV VLP
- Highly differentiated vaccine candidate with potentially compelling immunogenicity owing to its VLP structure
- Phase 3 program met its primary endpoint, demonstrating high seroresponse rate and fast onset of response
- Regulatory review underway in the US and Europe
CHIKV VLP is a virus-like particle (VLP)-based vaccine candidate for active immunization against chikungunya disease.
Two Phase 3 clinical trials of CHIKV VLP have been completed, evaluating the vaccine in more than 3,600 individuals aged 12 years and above.
Both studies met their primary endpoints, demonstrating that CHIKV VLP induced high levels of neutralizing antibodies against chikungunya, with antibody titers equal to or above the threshold agreed with authorities as a marker of seroprotection. The vaccine candidate was well-tolerated across both studies and adverse events were mainly mild or moderate in nature.
CHIKV VLP has received Breakthrough Therapy designation and Fast Track designation from the FDA, and PRIME designation from EMA.
Regulatory review with FDA and EMA is underway, with anticipated decisions in 2025.
Chikungunya virus is spread to people by infected mosquitoes. Symptoms include fever, joint pain, headache, muscle pain, joint swelling or rash, with some symptoms lasting months or even years. The geographic distribution of chikungunya has expanded to more than 100 countries and territories worldwide.